Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
20 studies found for:    reolysin
Show Display Options
Rank Status Study
1 Recruiting Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Condition: KRAS Mutant Metastatic Colorectal Cancer
Interventions: Biological: REOLYSIN®;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU);   Drug: Bevacizumab
2 Completed Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
3 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Conditions: Osteosarcoma;   Ewing Sarcoma Family Tumors;   Malignant Fibrous Histiocytoma;   Sarcoma, Synovial;   Fibrosarcoma;   Leiomyosarcoma
Intervention: Biological: REOLYSIN®
4 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
5 Recruiting Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed and Reolysin (and safety run-in);   Drug: Pemetrexed;   Drug: Docetaxel and Reolysin;   Drug: Docetaxel
6 Active, not recruiting Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Condition: Carcinoma, Non-small Cell Lung
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
7 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Condition: Malignant Glioma
Intervention: Biological: REOLYSIN®
8 Recruiting A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Reolysin
9 Recruiting Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Folfox plus Bevacizumab and reolysin;   Drug: Folfox plus Bevacizumab
10 Unknown  A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Biological: REOLYSIN;   Drug: Gemcitabine
11 Completed Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel
12 Active, not recruiting A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Condition: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Interventions: Biological: REOLYSIN;   Drug: Paclitaxel;   Drug: Carboplatin
13 Completed Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
14 Completed
Has Results
Viral Therapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Intervention: Biological: wild-type reovirus
15 Active, not recruiting Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Refractory Multiple Myeloma
Interventions: Biological: wild-type reovirus;   Other: diagnostic laboratory biomarker analysis
16 Recruiting Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Biological: wild-type reovirus;   Other: laboratory biomarker analysis
17 Completed Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Active, not recruiting Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus;   Other: laboratory biomarker analysis
19 Active, not recruiting Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: wild-type reovirus;   Drug: carboplatin;   Drug: paclitaxel;   Other: laboratory biomarker analysis
20 Active, not recruiting Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: wild-type reovirus;   Drug: paclitaxel

Indicates status has not been verified in more than two years